Anika Therapeutics Inc.

NASDAQ: ANIK · Real-Time Price · USD
8.90
0.26 (3.01%)
At close: Aug 15, 2025, 12:20 PM

Anika Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
28.22M 26.17M -1.29M 38.75M 41.92M 40.52M 42.97M 41.47M 44.3M 37.92M 39.62M 40.26M 39.66M 36.69M 35.82M 39.54M 38.15M 34.29M
Cost of Revenue
13.86M 11.49M -23.86M 37.31M 14.56M 15.89M 16.64M 16.52M 15.33M 15.08M 15.49M 17.48M 14.79M 14.89M 17.69M 16.51M 17.33M 13.32M
Gross Profit
14.36M 14.68M 22.57M 1.44M 27.36M 24.63M 26.33M 24.94M 28.97M 22.84M 24.13M 22.78M 24.86M 21.8M 18.13M 23.02M 20.81M 20.97M
Operating Income
-4.18M -4.28M 27.82M -28.02M 161K -5.06M -1.59M -7.67M -3.63M -12.55M -6.67M -5.8M -3.38M -3.55M -9.12M 1.3M 9.18M 1.26M
Interest Income
n/a n/a n/a 406K n/a n/a 577K 635K 561K n/a 276K 436K n/a n/a n/a n/a n/a n/a
Pretax Income
-3.97M -3.87M 28.56M -27.61M 756K -4.47M -63.2M -7.04M -3.07M -12.01M -6.39M -5.36M -3.29M -3.71M -9.17M 1.25M 9.13M 1.22M
Net Income
-3.97M -4.87M -21.86M -29.92M -88K -4.51M -63M -6.58M -2.74M -10.35M -4.91M -4.17M -2.84M -2.93M -5.79M 558K 6.53M 2.84M
Selling & General & Admin
12.23M 12.91M -4.89M 19.11M 19.81M 21.53M 20.34M 24.83M 23.69M 27M 23.05M 21.28M 21.27M 19.2M 20.43M 17.5M 17.99M 18.18M
Research & Development
6.31M 6.06M 2.74M 7.24M 7.4M 8.16M 7.58M 7.79M 8.91M 8.4M 7.75M 7.3M 6.97M 6.16M 6M 7.67M 7.29M 6.36M
Other Expenses
n/a n/a -3.1M 3.1M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
18.54M 18.96M -5.25M 29.46M 27.2M 29.69M 27.92M 32.62M 32.6M 35.4M 30.8M 28.58M 28.24M 25.36M 26.43M 25.17M 25.28M 24.54M
Interest Expense
629K n/a n/a n/a n/a 592K n/a n/a 561K n/a 276K 436K 96K n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
32.4M 30.45M -31.31M 66.77M 41.76M 45.59M 44.56M 49.14M 47.93M 50.48M 46.29M 46.06M 43.04M 40.25M 44.12M 41.69M 42.62M 37.85M
Income Tax Expense
681K 89K 2.87M 2.31M 844K 43K -204K -463K -329K -1.66M -1.48M -1.19M -442K -775K -3.38M 694K 2.6M -1.62M
Shares Outstanding (Basic)
14.33M 14.3M 14.58M 14.77M 14.84M 14.7M 14.65M 14.63M 14.69M 14.58M 14.64M 14.4M 14.21M 14.47M 14.37M 14.43M 14.39M 14.34M
Shares Outstanding (Diluted)
14.33M 14.3M 14.72M 14.77M 14.84M 14.7M 14.65M 14.63M 14.69M 14.65M 14.64M 14.6M 14.55M 14.47M 14.44M 14.65M 14.63M 14.44M
EPS (Basic)
-0.28 -0.34 -1.5 -2.03 -0.01 -0.31 -4.3 -0.45 -0.19 -0.71 -0.34 -0.29 -0.2 -0.2 -0.4 0.04 0.45 0.20
EPS (Diluted)
-0.28 -0.34 -1.5 -2.03 -0.01 -0.31 -4.3 -0.45 -0.19 -0.71 -0.34 -0.29 -0.2 -0.2 -0.4 0.04 0.45 0.20
EBITDA
-4.25M -2.69M 26.53M -25.42M 2.22M -1.87M 1.98M -4.13M -81K -9M -3M -2.3M 328K 63K -4.57M 5.24M -967K 1.26M
EBIT
n/a -4.28M 24.72M -27.61M 756K -4.47M -63.2M -7.67M -3.63M -12.55M -6.67M -5.8M -3.38M -3.55M -9.17M 1.25M 9.13M -3.56M
Depreciation & Amortization
-1.59M 1.59M 1.44M 2.19M 2.06M 2.6M 3.59M 4.04M 4.15M 3.55M 4.25M 3.97M 2.16M 2.08M 4.09M 3.99M 4.01M 3.91M